Dexlansoprazole

• GERD (Gastroesophageal Reflux Disease)
• Erosive Esophagitis
• Heartburn
• Acid Reflux

Dexlansoprazole is a proton pump inhibitor (PPI) with a dual delayed-release formulation used for the treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis. This medication offers extended acid suppression through a unique delivery system that provides two separate releases of the drug.

Mechanism of Action

Dexlansoprazole is the R-enantiomer of lansoprazole and a proton pump inhibitor that suppresses gastric acid secretion by specifically inhibiting the hydrogen-potassium ATPase enzyme system (the proton pump) at the secretory surface of gastric parietal cells. This enzyme is the final step in gastric acid production. Dexlansoprazole binds to the proton pump and blocks it irreversibly, reducing both basal and stimulated acid secretion regardless of the stimulus. The medication's dual delayed-release formulation releases drug at two different pH levels in the gastrointestinal tract, providing an initial release in the proximal duodenum and a second release in the more distal small intestine.

Available Formulations

Dexlansoprazole is available as delayed-release capsules in 30 mg and 60 mg strengths. The capsules can be swallowed whole or opened and the granules sprinkled on applesauce or mixed with water for patients who have difficulty swallowing. The capsules can be taken without regard to food, unlike some other PPIs that are recommended before meals. An orally disintegrating tablet is also available.

Medical Uses

Dexlansoprazole is FDA-approved for healing of all grades of erosive esophagitis (EE) for up to 8 weeks, maintaining healing of EE for up to 6 months, treatment of heartburn associated with symptomatic non-erosive GERD for 4 weeks, and treatment of heartburn associated with symptomatic non-erosive GERD in patients 12-17 years old for 4 weeks. The dual-release formulation provides extended duration of acid suppression compared to single-release PPIs.

Dosing Guidelines

For healing erosive esophagitis, the dose is 60 mg once daily for up to 8 weeks. For maintaining healing of EE, 30 mg once daily is used. For symptomatic non-erosive GERD, 30 mg once daily for 4 weeks is recommended. The medication can be taken at any time of day without regard to meals, offering flexibility compared to other PPIs. For patients with moderate hepatic impairment, doses should not exceed 30 mg daily. The orally disintegrating tablet should be allowed to dissolve on the tongue without water.

Important Safety Information

Long-term PPI use has been associated with increased risk of Clostridioides difficile-associated diarrhea, bone fractures (hip, wrist, spine), fundic gland polyps, hypomagnesemia, vitamin B12 deficiency, and acute interstitial nephritis. Patients should use the lowest effective dose for the shortest duration. PPIs may reduce the effectiveness of clopidogrel through CYP2C19 inhibition; alternative antiplatelet strategies should be considered. Acute interstitial nephritis can occur at any time during PPI therapy.

Drug Interactions

Dexlansoprazole is metabolized by CYP2C19 and CYP3A4. It may reduce the absorption of drugs dependent on gastric pH for bioavailability (ketoconazole, itraconazole, ampicillin esters, iron salts, mycophenolate mofetil). Increased levels of drugs metabolized by CYP2C19 (diazepam, phenytoin) may occur. Concomitant use with methotrexate may increase methotrexate toxicity. Warfarin anticoagulation should be monitored when starting or stopping dexlansoprazole. Use with atazanavir should be avoided.

Where Dexlansoprazole Sits Among Proton Pump Inhibitors

All proton pump inhibitors heal erosive esophagitis and relieve reflux symptoms at broadly similar rates, so dexlansoprazole is not a first choice for uncomplicated gastroesophageal reflux disease (GERD). Omeprazole and pantoprazole are inexpensive generics and are where treatment usually begins. Dexlansoprazole earns consideration in three narrower situations: a patient whose symptoms break through in the late evening or overnight despite a correctly timed morning dose, where the second delayed release extends acid suppression further into the day; a patient who cannot reliably take a pill thirty to sixty minutes before a meal, since dexlansoprazole does not depend on that timing; and a patient already on clopidogrel, where the CYP2C19 interaction that complicates omeprazole is a consideration, although pantoprazole is the more common substitute for that reason.

Esomeprazole and rabeprazole fill similar niches, and formulary coverage frequently settles the question. The National Institute of Diabetes and Digestive and Kidney Diseases reviews where medication fits alongside weight, meal timing, and head-of-bed elevation.

When Acid Suppression Does Not Work

A proton pump inhibitor that fails after a genuine trial usually signals something other than an inadequate dose. The commonest explanations are incorrect timing with the earlier-generation agents, poor adherence once symptoms partly improve, and a diagnosis that was never acid reflux: functional heartburn, esophageal hypersensitivity, eosinophilic esophagitis, gastroparesis, or cardiac pain. Chest discomfort attributed to reflux deserves a cardiac assessment before it is treated as heartburn, a distinction covered in our GERD versus heart attack guide.

Where the drug does work, the next question is duration. Non-erosive disease is treated for a defined course and then stepped down or stopped, ideally by tapering rather than abruptly, because rebound acid hypersecretion after a sudden stop mimics relapse and drives unnecessary restarts. Erosive esophagitis and Barrett esophagus are the situations where indefinite therapy is appropriate. The MedlinePlus dexlansoprazole monograph covers the patient-level details, and our gastrointestinal team reviews whether continued acid suppression is still indicated at each annual visit.

Special Populations

There are no adequate studies in pregnant women; animal studies showed no harm, but use during pregnancy only if clearly needed. It is unknown whether dexlansoprazole is excreted in human breast milk. Safety and efficacy have been established in adolescents 12-17 years for symptomatic GERD. Elderly patients do not require dose adjustment. Patients with moderate hepatic impairment should not exceed 30 mg daily; the medication has not been studied in severe hepatic impairment. No dose adjustment is needed for renal impairment.